| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 298380.KQ - ABL Bio Inc. | BUY | 1,669 @ KRW 135.538 | KRW 226,213 | The ETF bought 1669 new shares of 298380.KQ (ABL Bio Inc.). The shares were bought for an average price of 135.538 compared to the previous average buy price of 54.3244. This is 149.5% higher than average price of previous purchases of 298380.KQ. |
| EXAS - EXACT Sciences Corporation | BUY | 1,942 @ USD 101.74 | USD 197,579 | The ETF bought 1942 new shares of EXAS (EXACT Sciences Corporation). The shares were bought for an average price of 101.74 compared to the previous average buy price of 63.5437. This is 60.1% higher than average price of previous purchases of EXAS. |
| ILMN - Illumina Inc | BUY | 1,438 @ USD 134.35 | USD 193,195 | The ETF bought 1438 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 134.35 compared to the previous average buy price of 95.7764. This is 40.3% higher than average price of previous purchases of ILMN. |
| UCB.BR - UCB SA | BUY | 676 @ EUR 275.22 | EUR 186,049 | The ETF bought 676 new shares of UCB.BR (UCB SA). The shares were bought for an average price of 275.22 compared to the previous average buy price of 210.99. This is 30.4% higher than average price of previous purchases of UCB.BR. |
| TMO - Time Out Group plc | BUY | 307 @ USD 592.51 | USD 181,901 | The ETF bought 307 new shares of TMO (Time Out Group plc). The shares were bought for an average price of 592.51 compared to the previous average buy price of 420.31. This is 41.0% higher than average price of previous purchases of TMO. |
| IQV - IQVIA Holdings Inc | BUY | 789 @ USD 225.37 | USD 177,817 | The ETF bought 789 new shares of IQV (IQVIA Holdings Inc). The shares were bought for an average price of 225.37 compared to the previous average buy price of 163.188. This is 38.1% higher than average price of previous purchases of IQV. |
| NTRA - Natera Inc | BUY | 765 @ USD 228.84 | USD 175,063 | The ETF bought 765 new shares of NTRA (Natera Inc). The shares were bought for an average price of 228.84 compared to the previous average buy price of 178.391. This is 28.3% higher than average price of previous purchases of NTRA. |
| GMAB.CO - | BUY | 552 @ DKK 315.782 | DKK 174,312 | The ETF bought 552 new shares of GMAB.CO (). The shares were bought for an average price of 315.782 compared to the previous average buy price of 223.906. This is 41.0% higher than average price of previous purchases of GMAB.CO. |
| JNJ - Johnson & Johnson | BUY | 810 @ USD 207.35 | USD 167,954 | The ETF bought 810 new shares of JNJ (Johnson & Johnson). The shares were bought for an average price of 207.35 compared to the previous average buy price of 172.919. This is 19.9% higher than average price of previous purchases of JNJ. |
| MRK - Marks Electrical Group PLC | BUY | 1,560 @ USD 106.45 | USD 166,062 | The ETF bought 1560 new shares of MRK (Marks Electrical Group PLC). The shares were bought for an average price of 106.45 compared to the previous average buy price of 81.0381. This is 31.4% higher than average price of previous purchases of MRK. |
| MRK - Merck & Company Inc | BUY | 1,560 @ USD 106.45 | USD 166,062 | The ETF bought 1560 new shares of MRK (Merck & Company Inc). The shares were bought for an average price of 106.45 compared to the previous average buy price of 81.0381. This is 31.4% higher than average price of previous purchases of MRK. |
| BIIB - Biogen Inc | BUY | 931 @ USD 177.82 | USD 165,550 | The ETF bought 931 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 177.82 compared to the previous average buy price of 130.871. This is 35.9% higher than average price of previous purchases of BIIB. |
| ABBV - AbbVie Inc | BUY | 665 @ USD 229.31 | USD 152,491 | The ETF bought 665 new shares of ABBV (AbbVie Inc). The shares were bought for an average price of 229.31 compared to the previous average buy price of 202.648. This is 13.2% higher than average price of previous purchases of ABBV. |
| 068270.KS - CELLTRION INC | BUY | 1,067 @ KRW 140.391 | KRW 149,797 | The ETF bought 1067 new shares of 068270.KS (CELLTRION INC). The shares were bought for an average price of 140.391 compared to the previous average buy price of 121.755. This is 15.3% higher than average price of previous purchases of 068270.KS. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | BUY | 128 @ KRW 1166.81 | KRW 149,352 | The ETF bought 128 new shares of 207940.KS (SAMSUNG BIOLOGICS LTD). The shares were bought for an average price of 1166.81 compared to the previous average buy price of 773.248. This is 50.9% higher than average price of previous purchases of 207940.KS. |
| HOLX - Hologic Inc | BUY | 1,947 @ USD 74.56 | USD 145,168 | The ETF bought 1947 new shares of HOLX (Hologic Inc). The shares were bought for an average price of 74.56 compared to the previous average buy price of 66.4442. This is 12.2% higher than average price of previous purchases of HOLX. |
| GSK.L - GlaxoSmithKline PLC | BUY | 5,854 @ GBP 24.7253 | GBP 144,742 | The ETF bought 5854 new shares of GSK.L (GlaxoSmithKline PLC). The shares were bought for an average price of 24.7253 compared to the previous average buy price of 19.5232. This is 26.6% higher than average price of previous purchases of GSK.L. |
| A - Agilent Technologies Inc | BUY | 1,049 @ USD 137.95 | USD 144,710 | The ETF bought 1049 new shares of A (Agilent Technologies Inc). The shares were bought for an average price of 137.95 compared to the previous average buy price of 122.586. This is 12.5% higher than average price of previous purchases of A. |
| DHR - Danaher Corporation | BUY | 627 @ USD 230.4 | USD 144,461 | The ETF bought 627 new shares of DHR (Danaher Corporation). The shares were bought for an average price of 230.4 compared to the previous average buy price of 200.37. This is 15.0% higher than average price of previous purchases of DHR. |
| DHR - Danaher Corporation | BUY | 627 @ USD 230.4 | USD 144,461 | The ETF bought 627 new shares of DHR (Danaher Corporation). The shares were bought for an average price of 230.4 compared to the previous average buy price of 200.37. This is 15.0% higher than average price of previous purchases of DHR. |
| EW - Edwards Lifesciences Corp | BUY | 1,675 @ USD 85.33 | USD 142,928 | The ETF bought 1675 new shares of EW (Edwards Lifesciences Corp). The shares were bought for an average price of 85.33 compared to the previous average buy price of 74.7897. This is 14.1% higher than average price of previous purchases of EW. |
| NBIX - Neurocrine Biosciences Inc | BUY | 1,013 @ USD 140.6 | USD 142,428 | The ETF bought 1013 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 140.6 compared to the previous average buy price of 128.042. This is 9.8% higher than average price of previous purchases of NBIX. |
| AMGN - Amgen Inc | BUY | 434 @ USD 327.64 | USD 142,196 | The ETF bought 434 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 327.64 compared to the previous average buy price of 297.444. This is 10.2% higher than average price of previous purchases of AMGN. |
| MEDP - Medpace Holdings Inc | BUY | 246 @ USD 571.02 | USD 140,471 | The ETF bought 246 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 571.02 compared to the previous average buy price of 389.105. This is 46.8% higher than average price of previous purchases of MEDP. |
| GILD - Guild Esports Plc | BUY | 1,152 @ USD 121.6 | USD 140,083 | The ETF bought 1152 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 121.6 compared to the previous average buy price of 107.936. This is 12.7% higher than average price of previous purchases of GILD. |
| MDT - Medtronic PLC | BUY | 1,444 @ USD 96.05 | USD 138,696 | The ETF bought 1444 new shares of MDT (Medtronic PLC). The shares were bought for an average price of 96.05 compared to the previous average buy price of 90.5138. This is 6.1% higher than average price of previous purchases of MDT. |
| BMY - Bloomsbury Publishing Plc | BUY | 2,542 @ USD 53.46 | USD 135,895 | The ETF bought 2542 new shares of BMY (Bloomsbury Publishing Plc). The shares were bought for an average price of 53.46 compared to the previous average buy price of 53.3716. This is 0.2% higher than average price of previous purchases of BMY. |
| ISRG - Intuitive Surgical Inc | BUY | 238 @ USD 561.98 | USD 133,751 | The ETF bought 238 new shares of ISRG (Intuitive Surgical Inc). The shares were bought for an average price of 561.98 compared to the previous average buy price of 537.51. This is 4.6% higher than average price of previous purchases of ISRG. |
| PFE - Pfizer Inc | BUY | 5,228 @ USD 25.18 | USD 131,641 | The ETF bought 5228 new shares of PFE (Pfizer Inc). The shares were bought for an average price of 25.18 compared to the previous average buy price of 24.3591. This is 3.4% higher than average price of previous purchases of PFE. |
| GH - Guardant Health Inc | BUY | 1,281 @ USD 101.74 | USD 130,329 | The ETF bought 1281 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 101.74 compared to the previous average buy price of 56.8756. This is 78.9% higher than average price of previous purchases of GH. |
| MRNA - Moderna Inc | BUY | 3,995 @ USD 30.86 | USD 123,286 | The ETF bought 3995 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 30.86 compared to the previous average buy price of 25.9874. This is 18.7% higher than average price of previous purchases of MRNA. |
| EXEL - Exelixis Inc | BUY | 2,816 @ USD 43.58 | USD 122,721 | The ETF bought 2816 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.58 compared to the previous average buy price of 38.4103. This is 13.5% higher than average price of previous purchases of EXEL. |
| PODD - Insulet Corporation | BUY | 426 @ USD 282.92 | USD 120,524 | The ETF bought 426 new shares of PODD (Insulet Corporation). The shares were bought for an average price of 282.92 compared to the previous average buy price of 283.116. This is -0.1% lower than average price of previous purchases of PODD. |
| RVTY - Revvity Inc. | BUY | 1,213 @ USD 98.15 | USD 119,056 | The ETF bought 1213 new shares of RVTY (Revvity Inc.). The shares were bought for an average price of 98.15 compared to the previous average buy price of 99.6645. This is -1.5% lower than average price of previous purchases of RVTY. |
| ABT - Abbott Laboratories | BUY | 943 @ USD 124.19 | USD 117,111 | The ETF bought 943 new shares of ABT (Abbott Laboratories). The shares were bought for an average price of 124.19 compared to the previous average buy price of 124.72. This is -0.4% lower than average price of previous purchases of ABT. |
| BSX - Boston Scientific Corporation | BUY | 1,228 @ USD 94.71 | USD 116,304 | The ETF bought 1228 new shares of BSX (Boston Scientific Corporation). The shares were bought for an average price of 94.71 compared to the previous average buy price of 97.5595. This is -2.9% lower than average price of previous purchases of BSX. |
| BSX - MULSTRXSSXIMETFP | BUY | 1,228 @ USD 94.71 | USD 116,304 | The ETF bought 1228 new shares of BSX (MULSTRXSSXIMETFP). The shares were bought for an average price of 94.71 compared to the previous average buy price of 97.5595. This is -2.9% lower than average price of previous purchases of BSX. |
| AXSM - Axsome Therapeutics Inc | BUY | 560 @ USD 178.69 | USD 100,066 | The ETF bought 560 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 178.69 compared to the previous average buy price of 118.203. This is 51.2% higher than average price of previous purchases of AXSM. |
| DXCM - DexCom Inc | BUY | 1,495 @ USD 66.54 | USD 99,477 | The ETF bought 1495 new shares of DXCM (DexCom Inc). The shares were bought for an average price of 66.54 compared to the previous average buy price of 78.6853. This is -15.4% lower than average price of previous purchases of DXCM. |
| PTCT - PTC Therapeutics Inc | BUY | 1,277 @ USD 76.74 | USD 97,997 | The ETF bought 1277 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 76.74 compared to the previous average buy price of 57.2121. This is 34.1% higher than average price of previous purchases of PTCT. |
| TECH - Bio-Techne Corp | BUY | 1,620 @ USD 59.65 | USD 96,633 | The ETF bought 1620 new shares of TECH (Bio-Techne Corp). The shares were bought for an average price of 59.65 compared to the previous average buy price of 59.3092. This is 0.6% higher than average price of previous purchases of TECH. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 901 @ USD 105.01 | USD 94,614 | The ETF bought 901 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 105.01 compared to the previous average buy price of 69.0005. This is 52.2% higher than average price of previous purchases of RYTM. |
| LIVN - LivaNova PLC | BUY | 1,532 @ USD 60.64 | USD 92,900 | The ETF bought 1532 new shares of LIVN (LivaNova PLC). The shares were bought for an average price of 60.64 compared to the previous average buy price of 47.5492. This is 27.5% higher than average price of previous purchases of LIVN. |
| CRL - Creightons Plc | BUY | 447 @ USD 202.42 | USD 90,482 | The ETF bought 447 new shares of CRL (Creightons Plc). The shares were bought for an average price of 202.42 compared to the previous average buy price of 167.58. This is 20.8% higher than average price of previous purchases of CRL. |
| HALO - Halozyme Therapeutics Inc | BUY | 1,275 @ USD 70.31 | USD 89,645 | The ETF bought 1275 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 70.31 compared to the previous average buy price of 60.6783. This is 15.9% higher than average price of previous purchases of HALO. |
| RGEN - Repligen Corporation | BUY | 542 @ USD 164.35 | USD 89,078 | The ETF bought 542 new shares of RGEN (Repligen Corporation). The shares were bought for an average price of 164.35 compared to the previous average buy price of 146.379. This is 12.3% higher than average price of previous purchases of RGEN. |
| PME.AX - | BUY | 577 @ AUD 148.895 | AUD 85,912 | The ETF bought 577 new shares of PME.AX (). The shares were bought for an average price of 148.895 compared to the previous average buy price of 164.588. This is -9.5% lower than average price of previous purchases of PME.AX. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 20,257 @ USD 4.2 | USD 85,079 | The ETF bought 20257 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.2 compared to the previous average buy price of 5.13716. This is -18.2% lower than average price of previous purchases of RXRX. |
| TXG - 10X Genomics Inc | BUY | 5,111 @ USD 16.62 | USD 84,945 | The ETF bought 5111 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 16.62 compared to the previous average buy price of 12.6505. This is 31.4% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 5,111 @ USD 16.62 | USD 84,945 | The ETF bought 5111 new shares of TXG (Terex Corporation). The shares were bought for an average price of 16.62 compared to the previous average buy price of 12.6505. This is 31.4% higher than average price of previous purchases of TXG. |
| ALKS - Alkermes Plc | BUY | 2,994 @ USD 28.26 | USD 84,610 | The ETF bought 2994 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.26 compared to the previous average buy price of 30.5552. This is -7.5% lower than average price of previous purchases of ALKS. |
| SDGR - Schrodinger Inc | BUY | 4,678 @ USD 17.98 | USD 84,110 | The ETF bought 4678 new shares of SDGR (Schrodinger Inc). The shares were bought for an average price of 17.98 compared to the previous average buy price of 22.3078. This is -19.4% lower than average price of previous purchases of SDGR. |
| SRT3.DE - Sartorius AG | BUY | 287 @ EUR 291.202 | EUR 83,575 | The ETF bought 287 new shares of SRT3.DE (Sartorius AG). The shares were bought for an average price of 291.202 compared to the previous average buy price of 249.502. This is 16.7% higher than average price of previous purchases of SRT3.DE. |
| RCUS - Arcus Biosciences Inc | BUY | 3,584 @ USD 23.29 | USD 83,471 | The ETF bought 3584 new shares of RCUS (Arcus Biosciences Inc). The shares were bought for an average price of 23.29 compared to the previous average buy price of 9.26549. This is 151.4% higher than average price of previous purchases of RCUS. |
| DVAX - Dynavax Technologies Corporation | BUY | 5,417 @ USD 15.38 | USD 83,313 | The ETF bought 5417 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.38 compared to the previous average buy price of 12.7737. This is 20.4% higher than average price of previous purchases of DVAX. |
| DIA.MI - DiaSorin SpA | BUY | 1,032 @ EUR 80.3802 | EUR 82,952 | The ETF bought 1032 new shares of DIA.MI (DiaSorin SpA). The shares were bought for an average price of 80.3802 compared to the previous average buy price of 55.2655. This is 45.4% higher than average price of previous purchases of DIA.MI. |
| HLUN-B.CO - | BUY | 12,252 @ DKK 6.76563 | DKK 82,892 | The ETF bought 12252 new shares of HLUN-B.CO (). The shares were bought for an average price of 6.76563 compared to the previous average buy price of 6.04319. This is 12.0% higher than average price of previous purchases of HLUN-B.CO. |
| BIM.PA - BioMerieux | BUY | 644 @ EUR 128.679 | EUR 82,869 | The ETF bought 644 new shares of BIM.PA (BioMerieux). The shares were bought for an average price of 128.679 compared to the previous average buy price of 121.836. This is 5.6% higher than average price of previous purchases of BIM.PA. |
| MMS - LYXETFETUSITETFP | BUY | 958 @ USD 86.47 | USD 82,838 | The ETF bought 958 new shares of MMS (LYXETFETUSITETFP). The shares were bought for an average price of 86.47 compared to the previous average buy price of 75.7914. This is 14.1% higher than average price of previous purchases of MMS. |
| HRMY - Harmony Biosciences Holdings | BUY | 2,212 @ USD 37.38 | USD 82,685 | The ETF bought 2212 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 37.38 compared to the previous average buy price of 32.7877. This is 14.0% higher than average price of previous purchases of HRMY. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 1,669 @ USD 49.47 | USD 82,565 | The ETF bought 1669 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 49.47 compared to the previous average buy price of 36.8238. This is 34.3% higher than average price of previous purchases of SUPN. |
| TGTX - TG Therapeutics Inc | BUY | 2,799 @ USD 29.28 | USD 81,955 | The ETF bought 2799 new shares of TGTX (TG Therapeutics Inc). The shares were bought for an average price of 29.28 compared to the previous average buy price of 33.6626. This is -13.0% lower than average price of previous purchases of TGTX. |
| QDEL - Quidel Corporation | BUY | 2,842 @ USD 28.78 | USD 81,793 | The ETF bought 2842 new shares of QDEL (Quidel Corporation). The shares were bought for an average price of 28.78 compared to the previous average buy price of 29.517. This is -2.5% lower than average price of previous purchases of QDEL. |
| RLAY - Relay Therapeutics Inc | BUY | 9,971 @ USD 8.18 | USD 81,563 | The ETF bought 9971 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.18 compared to the previous average buy price of 5.43742. This is 50.4% higher than average price of previous purchases of RLAY. |
| IPN.PA - Ipsen SA | BUY | 595 @ EUR 136.435 | EUR 81,179 | The ETF bought 595 new shares of IPN.PA (Ipsen SA). The shares were bought for an average price of 136.435 compared to the previous average buy price of 121.69. This is 12.1% higher than average price of previous purchases of IPN.PA. |
| STOK - Stoke Therapeutics Inc | BUY | 2,617 @ USD 30.9 | USD 80,865 | The ETF bought 2617 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 30.9 compared to the previous average buy price of 12.2186. This is 152.9% higher than average price of previous purchases of STOK. |
| PRAX - Praxis Precision Medicines Inc | BUY | 281 @ USD 286.4 | USD 80,478 | The ETF bought 281 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 286.4 compared to the previous average buy price of 181.344. This is 57.9% higher than average price of previous purchases of PRAX. |
| DYVOX.ST - | BUY | 7,505 @ SEK 10.7168 | SEK 80,430 | The ETF bought 7505 new shares of DYVOX.ST (). The shares were bought for an average price of 10.7168 compared to the previous average buy price of 6.4052. This is 67.3% higher than average price of previous purchases of DYVOX.ST. |
| 237690.KQ - ST Pharm Co.,Ltd. | BUY | 1,007 @ KRW 79.7282 | KRW 80,286 | The ETF bought 1007 new shares of 237690.KQ (ST Pharm Co.,Ltd.). The shares were bought for an average price of 79.7282 compared to the previous average buy price of 55.9995. This is 42.4% higher than average price of previous purchases of 237690.KQ. |
| NUVB - Nuvation Bio Inc | BUY | 9,313 @ USD 8.58 | USD 79,906 | The ETF bought 9313 new shares of NUVB (Nuvation Bio Inc). The shares were bought for an average price of 8.58 compared to the previous average buy price of 7.10591. This is 20.7% higher than average price of previous purchases of NUVB. |
| IART - Integra LifeSciences Holdings | BUY | 6,566 @ USD 12.01 | USD 78,858 | The ETF bought 6566 new shares of IART (Integra LifeSciences Holdings). The shares were bought for an average price of 12.01 compared to the previous average buy price of 19.6895. This is -39.0% lower than average price of previous purchases of IART. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | BUY | 24,500 @ HKD 3.13641 | HKD 76,842 | The ETF bought 24500 new shares of 2252.HK (SHANGHAI MICROPORT MEDBOT CLASS H). The shares were bought for an average price of 3.13641 compared to the previous average buy price of 3.2143. This is -2.4% lower than average price of previous purchases of 2252.HK. |
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 15.391 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 15.391. The average price that 007390.KQ shares were previous bought at was KRW 21.3643. The current market price is -28.0% lower than average price they were purchased at. The value of the holding in 007390.KQ has increased by KRW 16,308 (USD $11) compared to the previous valuation of NatureCell Co.,Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 30.0194 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 30.0194. The average price that 039200.KQ shares were previous bought at was KRW 21.1692. The current market price is 41.8% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 54,563 (USD $38) compared to the previous valuation of Oscotec Inc. |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.9509 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.9509. The average price that 096530.KQ shares were previous bought at was KRW 17.5828. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 18,644 (USD $13) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.68725 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.68725. The average price that 13.HK shares were previous bought at was HKD 2.99796. The current market price is -10.4% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 24,395 (USD $3,133) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.99127 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 2.85921 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 2.85921. The average price that 1877.HK shares were previous bought at was HKD 2.5435. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 21,928 (USD $2,817) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 6.85929 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 6.85929. The average price that 2162.HK shares were previous bought at was HKD 5.38428. The current market price is 27.4% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 1,728 (USD $222) compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 33.2779 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 33.2779. The average price that 302440.KS shares were previous bought at was KRW 36.1184. The current market price is -7.9% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 5,680 (USD $4) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 85.2052 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 85.2052. The average price that 326030.KS shares were previous bought at was KRW 78.0703. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 43,728 (USD $30) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 30.47 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 30.47. The average price that 328130.KQ shares were previous bought at was KRW 36.1354. The current market price is -15.7% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 62,435 (USD $43) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.50532 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.50532. The average price that 3933.HK shares were previous bought at was HKD 1.66691. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 19,661 (USD $2,525) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.7602 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.7602. The average price that 4523.T shares were previous bought at was JPY 28.5706. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 10,681 (USD $68) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.3718 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.3718. The average price that 4549.T shares were previous bought at was JPY 13.7463. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 450 (USD $3) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.5789 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.5789. The average price that 4587.T shares were previous bought at was JPY 11.0208. The current market price is -4.0% lower than average price they were purchased at. The value of the holding in 4587.T has increased by JPY 1,362 (USD $9) compared to the previous valuation of PeptiDream Inc. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.0653 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.0653. The average price that 4887.T shares were previous bought at was JPY 13.3528. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 1,816 (USD $12) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.07712 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.07712. The average price that 4974.T shares were previous bought at was JPY 5.70398. The current market price is -11.0% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 299 (USD $2) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.85088 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.85088. The average price that 6869.T shares were previous bought at was JPY 14.7177. The current market price is -33.1% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 6,341 (USD $40) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 32.1295 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 32.1295. The average price that 6951.T shares were previous bought at was JPY 33.0007. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 2,024 (USD $13) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.0648 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.0648. The average price that 7575.T shares were previous bought at was JPY 10.1362. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 712 (USD $5) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 26.6181 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 26.6181. The average price that 7701.T shares were previous bought at was JPY 26.482. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 9,700 (USD $62) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.7598 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.7598. The average price that 7747.T shares were previous bought at was JPY 16.9935. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 5,701 (USD $36) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 9.45158 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 9.45158. The average price that 9995.HK shares were previous bought at was HKD 9.68574. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 40,651 (USD $5,221) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.43 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.43. The average price that ABCL shares were previous bought at was USD 3.60785. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 2,770 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.29 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.29. The average price that ACAD shares were previous bought at was USD 20.3943. The current market price is 28.9% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 62,953 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 63.34 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 63.34. The average price that ACLX shares were previous bought at was USD 64.8526. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in ACLX has fallen by USD 94,245 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 15.91 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 15.91. The average price that ADPT shares were previous bought at was USD 7.03745. The current market price is 126.1% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 60,356 compared to the previous valuation of Adaptive Biotechnologies Corp |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 11.42 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 11.42. The average price that AMLX shares were previous bought at was USD 13.2037. The current market price is -13.5% lower than average price they were purchased at. The value of the holding in AMLX has fallen by USD 58,580 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 44.95 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 44.95. The average price that ANAB shares were previous bought at was USD 24.2251. The current market price is 85.6% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 91,310 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.24999 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.24999. The average price that ARCT shares were previous bought at was USD 12.3242. The current market price is -49.3% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 3,129 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.47 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.47. The average price that ARVN shares were previous bought at was USD 11.3713. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in ARVN has fallen by USD 33,016 compared to the previous valuation of Arvinas Inc |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 25.22 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 25.22. The average price that ASTH shares were previous bought at was USD 26.4973. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ASTH has increased by USD 19,892 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 39.27 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 39.27. The average price that ATRC shares were previous bought at was USD 33.6752. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 17,232 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.35 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.35. The average price that AUPH shares were previous bought at was USD 11.6813. The current market price is 31.4% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 95,708 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AXGN - Axogen Inc | HOLD | 0 @ USD 31 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 31. The average price that AXGN shares were previous bought at was USD 18.5561. The current market price is 67.1% higher than average price they were purchased at. The value of the holding in AXGN has fallen by USD 91,446 compared to the previous valuation of Axogen Inc |
| BANB.SW - | HOLD | 0 @ CHF 75.7892 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 75.7892. The average price that BANB.SW shares were previous bought at was CHF 65.7954. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 6,822 (USD $8,613) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 30.3352 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 30.3352. The average price that BAVA.CO shares were previous bought at was DKK 25.5909. The current market price is 18.5% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 30,867 (USD $4,856) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.5 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.5. The average price that BCRX shares were previous bought at was USD 7.7452. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 77,593 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 27.14 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 27.14. The average price that BEAM shares were previous bought at was USD 18.7837. The current market price is 44.5% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 71,172 compared to the previous valuation of Beam Therapeutics Inc |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 305.27 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 305.27. The average price that BIO shares were previous bought at was USD 290.943. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 58,637 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 305.27 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 305.27. The average price that BIO shares were previous bought at was USD 290.943. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 58,637 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 33.7978 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 33.7978. The average price that BIOA-B.ST shares were previous bought at was SEK 30.1726. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 4,140 (USD $451) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 23.89 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 23.89. The average price that BLFS shares were previous bought at was USD 25.5106. The current market price is -6.4% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 16,349 compared to the previous valuation of BioLife Solutions Inc |
| CDNA - Caredx Inc | HOLD | 0 @ USD 19.14 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 19.14. The average price that CDNA shares were previous bought at was USD 19.2054. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in CDNA has increased by USD 18,563 compared to the previous valuation of Caredx Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 8.74 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.74. The average price that CERT shares were previous bought at was USD 10.3575. The current market price is -15.6% lower than average price they were purchased at. The value of the holding in CERT has fallen by USD 9,827 compared to the previous valuation of Certara Inc |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 41.79 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 41.79. The average price that CGON shares were previous bought at was USD 41.5514. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 20,129 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 106.126 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 106.126. The average price that CHEMM.CO shares were previous bought at was DKK 79.3096. The current market price is 33.8% higher than average price they were purchased at. The value of the holding in CHEMM.CO has fallen by DKK 41,749 (USD $6,569) compared to the previous valuation of |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.15 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.15. The average price that CPRX shares were previous bought at was USD 22.4625. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 28,180 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 65.74 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 65.74. The average price that CRVL shares were previous bought at was USD 111.286. The current market price is -40.9% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 68,878 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 38.54 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 38.54. The average price that CSTL shares were previous bought at was USD 21.8554. The current market price is 76.3% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 12,517 compared to the previous valuation of Castle Biosciences Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 4.92 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 4.92. The average price that CTKB shares were previous bought at was USD 5.6893. The current market price is -13.5% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 20,530 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 8.85 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 8.85. The average price that DAWN shares were previous bought at was USD 8.51758. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in DAWN has fallen by USD 43,120 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.17126 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.17126. The average price that EKTA-B.ST shares were previous bought at was SEK 5.66491. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 6,883 (USD $749) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 11.66 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 11.66. The average price that EMBC shares were previous bought at was USD 12.8193. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 15,236 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 17.639 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 17.639. The average price that EUZ.DE shares were previous bought at was EUR 18.6179. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 14,672 (USD $17,240) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 3.89 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 3.89. The average price that EVH shares were previous bought at was USD 9.2746. The current market price is -58.1% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 14,018 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.48918 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.48918. The average price that EVT.DE shares were previous bought at was EUR 6.56011. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 15,958 (USD $18,751) compared to the previous valuation of Evotec SE however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 16.81 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 16.81. The average price that FTRE shares were previous bought at was USD 10.8459. The current market price is 55.0% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 48,937 compared to the previous valuation of Fortrea Holdings Inc. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 33.0922 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 33.0922. The average price that GLPG.AS shares were previous bought at was EUR 29.4493. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 9,431 (USD $11,082) compared to the previous valuation of Galapagos NV however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.02 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.02. The average price that IBRX shares were previous bought at was USD 2.80572. The current market price is -28.0% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 11,034 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 33.85 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 33.85. The average price that IDYA shares were previous bought at was USD 24.0067. The current market price is 41.0% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 76,528 compared to the previous valuation of Ideaya Biosciences Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.52 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.52. The average price that IOVA shares were previous bought at was USD 2.41741. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in IOVA has fallen by USD 70,029 compared to the previous valuation of Iovance Biotherapeutics Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 13.65 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 13.65. The average price that JANX shares were previous bought at was USD 24.6116. The current market price is -44.5% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 10,353 compared to the previous valuation of Janux Therapeutics Inc |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.005 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.005. The average price that KNSA shares were previous bought at was USD 40.3852. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 39,436 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.335 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.335. The average price that KURA shares were previous bought at was USD 10.609. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in KURA has fallen by USD 5,179 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.27 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.27. The average price that LAB shares were previous bought at was USD 1.36709. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in LAB has fallen by USD 4,163 compared to the previous valuation of Standard Biotools Inc |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 190.11 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 190.11. The average price that LGND shares were previous bought at was USD 127.891. The current market price is 48.7% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 24,230 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 67.27 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 67.27. The average price that LNTH shares were previous bought at was USD 76.5173. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in LNTH has increased by USD 60,144 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 680.458 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 680.458. The average price that LONN.SW shares were previous bought at was CHF 642.271. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 34,472 (USD $43,524) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.4 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.4. The average price that MRVI shares were previous bought at was USD 2.98184. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 23,522 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.14 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.14. The average price that MYGN shares were previous bought at was USD 8.54619. The current market price is -28.2% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 1,094 compared to the previous valuation of Myriad Genetics Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 7 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 7. The average price that NEOG shares were previous bought at was USD 9.86113. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 2,587 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.647 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.647. The average price that NEU.AX shares were previous bought at was AUD 8.98382. The current market price is 40.8% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 37,215 (USD $24,853) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 138.673 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 138.673. The average price that NOVN.SW shares were previous bought at was CHF 114.81. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 41,547 (USD $52,456) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.13 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.13. The average price that NVAX shares were previous bought at was USD 6.53355. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 74,406 compared to the previous valuation of Novavax Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.13 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.13. The average price that NVAX shares were previous bought at was USD 6.53355. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 74,406 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.12 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.12. The average price that NVCR shares were previous bought at was USD 16.2788. The current market price is -19.4% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 24,016 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.728 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.728. The average price that ONT.L shares were previous bought at was GBP 1.72755. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 659 (USD $888) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.84 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.84. The average price that PACB shares were previous bought at was USD 1.38552. The current market price is 32.8% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 10,887 compared to the previous valuation of Pacific Biosciences of California |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.71924 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.71924. The average price that PHARM.AS shares were previous bought at was EUR 0.920936. The current market price is 86.7% higher than average price they were purchased at. The value of the holding in PHARM.AS has increased by EUR 37,234 (USD $43,752) compared to the previous valuation of Pharming Group NV however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 89.7815 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 89.7815. The average price that PHM.MC shares were previous bought at was EUR 87.2276. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 29,676 (USD $34,871) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.57 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.57. The average price that RGNX shares were previous bought at was USD 8.80724. The current market price is 54.1% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 44,291 compared to the previous valuation of Regenxbio Inc |
| RO.SW - | HOLD | 0 @ CHF 424.116 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 424.116. The average price that RO.SW shares were previous bought at was CHF 371.765. The current market price is 14.1% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 1,800 (USD $2,273) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 415.259 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 415.259. The average price that ROG.SW shares were previous bought at was CHF 328.265. The current market price is 26.5% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 43,039 (USD $54,340) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 26.0552 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 26.0552. The average price that SECT-B.ST shares were previous bought at was SEK 27.9755. The current market price is -6.9% lower than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 207,340 (USD $22,563) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 94.3885 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 94.3885. The average price that SFZN.SW shares were previous bought at was CHF 123.442. The current market price is -23.5% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 10,872 (USD $13,727) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 18.11 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 18.11. The average price that SLP shares were previous bought at was USD 25.9621. The current market price is -30.2% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 2,175 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.31 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.31. The average price that SRPT shares were previous bought at was USD 44.2759. The current market price is -51.9% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 25,359 compared to the previous valuation of Sarepta Therapeutics Inc |
| TECN.SW - | HOLD | 0 @ CHF 162.586 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 162.586. The average price that TECN.SW shares were previous bought at was CHF 195.138. The current market price is -16.7% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 6,014 (USD $7,593) compared to the previous valuation of however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 21.55 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 21.55. The average price that TNDM shares were previous bought at was USD 21.1819. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in TNDM has fallen by USD 35,522 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 32.39 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 32.39. The average price that TWST shares were previous bought at was USD 36.0684. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 45,477 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.39 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.39. The average price that VCYT shares were previous bought at was USD 34.8676. The current market price is 21.6% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 25,671 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.94 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.94. The average price that VIR shares were previous bought at was USD 7.17028. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 10,995 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.94 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.94. The average price that VIR shares were previous bought at was USD 7.17028. The current market price is -17.2% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 10,995 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.45617 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.45617. The average price that VLA.PA shares were previous bought at was EUR 2.93259. The current market price is 52.0% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 14,735 (USD $17,314) compared to the previous valuation of Valneva SE however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 8.25 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 8.25. The average price that VNDA shares were previous bought at was USD 4.89461. The current market price is 68.6% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 38,525 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 30.68 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 30.68. The average price that VRDN shares were previous bought at was USD 30.2047. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in VRDN has fallen by USD 44,129 compared to the previous valuation of Viridian Therapeutics Inc |
| XVIVO.ST - | HOLD | 0 @ SEK 19.6937 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 19.6937. The average price that XVIVO.ST shares were previous bought at was SEK 39.4797. The current market price is -50.1% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 16,142 (USD $1,757) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.62 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.62. The average price that ZYME shares were previous bought at was USD 18.5094. The current market price is 43.8% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 17,814 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |